27 completed, 14 recruiting, 14 unknown, 9 active not recruiting. 52 Phase 2, 19 Phase 1, 3 Not applicable, 2 Phase 3.
Follow Neuroendocrine Carcinoma: new trials by email Literature Review of Neuroendocrine Carcinoma trials Research Report on Neuroendocrine Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-21 |
| A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate PET/CT, 177Lu-DTPA-SC16.56 - Neuroendocrine Tumor of the Lung, Neuroendocrine Carcinoma of Lung | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2026-09-01 | 2026-08-06 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) Standard of Care Chemotherapy, Tarlatamab - Neuroendocrine Carcinoma | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 129 | 2026-02-06 | 2026-02-11 |
| ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma ZG006, ZG005 - Small Cell Lung Cancer, Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 350 | 2025-09-23 | 2026-01-05 |
| SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab - Neuroendocrine Carcinoma, Neuroendocrine Tumors | Phase 1 | Recruiting | Peter Hosein, MD | 36 | 2025-05-19 | 2026-04-28 |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. ZG006 - Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 78 | 2024-08-29 | 2024-12-16 |
| Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies CID-078 Monotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | Circle Pharma | 220 | 2024-08-14 | 2026-08-26 |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Dostarlimab, Chemotherapy - Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma | Phase 2 | Recruiting | UNICANCER | 120 | 2024-07-23 | 2025-12-02 |
| Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. ZG005, Etoposide, Cisplatin - Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 93 | 2024-05-30 | 2024-06-14 |
| Clinical Application of the J-PET Scanner Prototype J-PET scan - Prostate Cancer, Prostatic Hyperplasia | Recruiting | Jagiellonian University | 25 | 2024-03-07 | 2025-02-19 | |
| Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma ZG006 - Small Cell Lung Cancer, Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 54 | 2023-10-27 | 2026-01-05 |
| A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. Surufatinib and Serplulimab - Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2023-06-21 | 2026-07-14 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas RO7616789, Tocilizumab - Small Cell Lung Cancer, Neuroendocrine Carcinoma | Phase 1 | Completed | Hoffmann-La Roche | 41 | 2023-01-23 | 2025-03-10 |
| Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms 18F-FDG, 64Cu-Dotatate - GEP-NET, Neuroendocrine Tumors | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 200 | 2023-01-17 | 2023-11-22 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
| NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg) - Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 1 | Completed | Amr Mohamed MD | 15 | 2022-12-15 | 2026-08-10 |
| Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy Surufatinib, Sintilimab - Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 60 | 2022-07-01 | 2022-11-25 |
| Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients 18F-FDG, Injection of hyperpolarized [1-13C]Pyruvate, PET/MR/MRS/MRSI scanning - Breast Cancer, Neuroendocrine Tumors | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 15 | 2022-05-18 | 2024-05-14 |
| Neuroendocrine Tumors - Patient Reported Outcomes Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor | Active not recruiting | University of Iowa | 2539 | 2022-05-10 | 2026-08-20 |
Showing 20 of 74. Sign in to see all of them.
Carcinoma, Neuroendocrine (74) · Neuroendocrine Tumors (23) · Small Cell Lung Carcinoma (11) · Neoplasms (6) · Adenoma, Islet Cell (5) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Breast Neoplasms (4) · Carcinoid Tumor (4) · Carcinoma, Islet Cell (4) · Gastro-enteropancreatic neuroendocrine tumor (4) · Neoplasm Metastasis (4) · Carcinoma, Merkel Cell (3) · Melanoma (3) · Pancreatic Neoplasms (3)
Adenocarcinoma (74) · Neoplasms by Histologic Type (74) · Neoplasms, Germ Cell and Embryonal (74) · Neoplasms, Glandular and Epithelial (74) · Neoplasms, Nerve Tissue (74) · Neuroectodermal Tumors (74) · Carcinoma (72) · Neoplasms (68) · Neuroendocrine Tumors (51) · Neoplasms by Site (32) · Lung Diseases (16) · Respiratory Tract Diseases (16) · Respiratory Tract Neoplasms (16) · Thoracic Neoplasms (16) · Bronchial Neoplasms (14)
Everolimus (6) · Nivolumab (6) · Cisplatin (5) · Etoposide (5) · Bevacizumab (4) · Carboplatin (4) · Ipilimumab (4) · Temozolomide (4) · Fluorouracil (3) · Irinotecan (3) · pembrolizumab (3) · Capecitabine (2) · Disulfides (2) · Drug Therapy (2) · Fluorodeoxyglucose F18 (2)
M.D. Anderson Cancer Center (5) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (5) · Peking University (4) · Copenhagen University Hospital, Rigshospitalet (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · National Cancer Institute (NCI) (3) · Callisto Pharmaceuticals (2) · Intergroupe Francophone de Cancerologie Thoracique (2) · Memorial Sloan Kettering Cancer Center (2) · Ochsner Health System (2) · Peking Union Medical College Hospital (2) · SCRI Development Innovations, LLC (2) · Amr Mohamed MD (1) · Asan Medical Center (1) · Burzynski Research Institute (1)
United States (36) · China (14) · France (7) · Italy (6) · Denmark (4) · Canada (3) · Germany (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1)
Jason Wu (4) · Andreas Kjaer, MD (2) · Chunmei Bai, M.D. (2) · Jonathan Strosberg, M.D. (2) · Alberto Larghi, PhD (1) · Alex Adjei, MD, PhD (1) · Amber Williams, MSN, RN, OCN (1) · Amr Mohamed, MD (1) · Andrea M Isidori, MD, PhD (1) · Baek-Yeol Ryoo, MD (1) · Carl M Gay, MD,PHD (1)
PMID 14673042, PMID 16877720, PMID 23516312, PMID 25426617, PMID 25991462, PMID 26678657, PMID 26769865, PMID 30158287, PMID 30523756, PMID 30865533, PMID 31058975, PMID 32029495, PMID 32392558, PMID 32690499, PMID 32860331, PMID 33234490, PMID 34110489, PMID 35389428, PMID 35504244, PMID 36283927, PMID 37287870, PMID 37478883, PMID 39002347, PMID 39945192, PMID 41209655, PMID 41572426, PMID 41774886, PMID 42043735, PMID 42129445, PMID 42393461
2023 (1), U10CA021115 (1), U10CA180820 (1), U24CA196172 (1)